In addition to previous reports [68,69], we found increased baseline but impaired BCR-mediated PI3K pathway activation, especially in the CD21low B cells of CVID patients, providing potential therapeutic options to target these cells by specific inhibitors of PI3Kδ or mTOR. The gene discussed is BCR; the disease is common variable immunodeficiency.